Annual Report 2019
Department of Genetic Medicine and Services
Takeshi Kuwata, Kazuya Tsuchihara, Toru Mukohara, Sachiyo Mimaki, Yumie Hiraoka, Takahiro Kogawa, Kennichi Harano, Shingo Matsumoto
Introduction
The Department of Genetic Medicine and Services was newly established in May 2016, to handle genetic as well as genomic testing and related issues, including genetic counseling, conducted in the National Cancer Center Hospital East (NCCHE).
The Team and What We Do
The aim of the Department of Genetic Medicine and Services is to deal with the following subjects:
1) Genetic counseling
2) Genetic/genomic testing
3) Ethical issues related to genetic/genomic medicine
4) Educating people on genetic/genomic medicine
5) Regulating the storage and usage of genetic/genomic information
6) Other matters related to genetic/genomic medicine
Accordingly, members of the department with various specialties were assembled, including medical doctors, nurses, genetic counselors and medical technicians from different clinical departments or research laboratories.
The Outpatient Genetic Counseling Clinic provides genetic counseling and genetic testing for cancer patients and their relatives with familial history and/or specific features suspected for familial cancers. From April 2019 to March 2020, 77 new clients visited the Clinic, a total of 149 genetic counseling sessions were held and 65 genetic testing sessions were provided. Consequently, by March 2020, a total of 281 clients had visited the Clinic (Figure 1). The department also participated in an outpatient clinic specializing in Hereditary Breast and Ovary Cancer (HBOC) syndrome established by the Department of Breast and Medical Oncology.
For conducting precision oncology, our hospital is designated as one of the Cancer Genome Medical Core Hospitals in Japan and cooperates with 9 affiliated hospitals, especially for providing cancer genome profiling (CGP) tests. Under the national health care system, by March 2020, we had performed 227 CGP tests and held expert panels for 311 patients including 97 patients in affiliated hospitals.
Research activities
Our Outpatient Genetic Counseling Clinic is participating in the NCC Research and Development Fund program (25-A-1) and provides genetic testing.
Clinical trials
Our Outpatient Genetic Counseling Clinic supports and provides genetic counseling for patients willing to participate in clinical trials where genetic tests are required.
Education
We educated medical doctors wishing to become board-certified geneticians by attending the Outpatient Genetic Counseling Clinic. We also provided an intramural educational seminar for medical doctors and co-medicals to familiarize them with genetic and genomic medicine and provide precision medicine for all cancer patients and their families visiting our hospital. As a Cancer Genome Medical Core Hospital, we also provide seminars and lectures for educating doctors as well as co-medicals working at affiliated hospitals.
Future prospects
We will continue to provide genetic counseling and genetic testing for possible familial cancer patients/families. For precision oncology, we will conduct CGP tests under the national health care system and participate in several clinical trials using new technologies including liquid biopsy and whole genome/exome sequences. We will also continue to provide education programs for medical doctors and paramedics working in our hospital as well as affiliated hospitals. Our recent aim is to establish a genomic testing pipeline from research to clinic to accelerate the development of medical and diagnostic devices for genome medicine.
List of papers published in 2019
Journal
1. Kubota Y, Kawazoe A, Sasaki A, Mishima S, Sawada K, Nakamura Y, Kotani D, Kuboki Y, Taniguchi H, Kojima T, Doi T, Yoshino T, Ishii G, Kuwata T, Shitara K. The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer. Clin Cancer Res, 26:3784-3790, 2020
2. Sugita S, Kinoshita T, Kuwata T, Tokunaga M, Kaito A, Watanabe M, Tonouchi A, Sato R, Nagino M. Long-term oncological outcomes of laparoscopic versus open transhiatal resection for patients with Siewert type II adenocarcinoma of the esophagogastric junction. Surg Endosc, 2020
3. Mimaki S, Watanabe M, Kinoshita M, Yamashita R, Haeno H, Takemura S, Tanaka S, Marubashi S, Totsuka Y, Shibata T, Nakagama H, Ochiai A, Nakamori S, Kubo S, Tsuchihara K. Multifocal origin of occupational cholangiocarcinoma revealed by comparison of multilesion mutational profiles. Carcinogenesis, 41:368-376, 2020
4. Takehara K, Yamashita N, Watanabe R, Teramoto N, Tsuda H, Motohashi T, Harano K, Nakanishi T, Tokunaga H, Susumu N, Ueda Y, Yokoyama Y, Saito T. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma. Gynecol Oncol, 157:115-120, 2020
5. Shingaki S, Kogawa T, Shimokawa M, Harano K, Naito Y, Kusuhara S, Fujimoto Y, Matsubara N, Hosono A, Mukai H, Onishi T, Hojo T, Mukohara T. Use of eribulin as an earlier-line chemotherapy for patients with HER2-negative metastatic breast cancer. J Cancer, 11:4099-4105, 2020
6. Kogawa T, Fujii T, Wu J, Harano K, Fouad TM, Liu DD, Shen Y, Masuda H, Krishnamurthy S, Chavez-MacGregor M, Lim B, Murthy RK, Valero V, Tripathy D, Ueno NT. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab. Oncologist, 25:e909-e919, 2020
7. Suzuki J, Kojima M, Aokage K, Sakai T, Nakamura H, Ohara Y, Tane K, Miyoshi T, Sugano M, Fujii S, Kuwata T, Ochiai A, Ito M, Suzuki K, Tsuboi M, Ishii G. Clinicopathological characteristics associated with necrosis in pulmonary metastases from colorectal cancer. Virchows Arch, 474:569-575, 2019
8. Omori T, Aokage K, Nakamura H, Katsumata S, Miyoshi T, Sugano M, Kojima M, Fujii S, Kuwata T, Ochiai A, Ikeda N, Tsuboi M, Ishii G. Growth patterns of small peripheral squamous cell carcinoma of the lung and their impacts on pathological and biological characteristics of tumor cells. J Cancer Res Clin Oncol, 145:1773-1783, 2019
9. Oki T, Aokage K, Ueda T, Sugano M, Tane K, Miyoshi T, Kojima M, Fujii S, Kuwata T, Ochiai A, Funai K, Tsuboi M, Ishii G. Proportion of goblet cell is associated with malignant potential in invasive mucinous adenocarcinoma of the lung. Pathol Int, 69:526-535, 2019
10. Sasaki A, Nakamura Y, Mishima S, Kawazoe A, Kuboki Y, Bando H, Kojima T, Doi T, Ohtsu A, Yoshino T, Kuwata T, Akimoto T, Shitara K. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer, 22:793-802, 2019
11. Kaito A, Kuwata T, Tokunaga M, Shitara K, Sato R, Akimoto T, Kinoshita T. HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer. World J Clin Cases, 7:1964-1977, 2019
12. Fujii S, Yoshino T, Yamazaki K, Muro K, Yamaguchi K, Nishina T, Yuki S, Shinozaki E, Shitara K, Bando H, Mimaki S, Nakai C, Matsushima K, Suzuki Y, Akagi K, Yamanaka T, Nomura S, Esumi H, Sugiyama M, Nishida N, Mizokami M, Koh Y, Abe Y, Ohtsu A, Tsuchihara K. Histopathological factors affecting the extraction of high quality genomic DNA from tissue sections for next-generation sequencing. Biomed Rep, 11:171-180, 2019 13. Tonouchi A, Sugano M, Tokunaga M, Sugita S, Watanabe M, Sato R, Kaito A, Akimoto T, Ochiai A, Kinoshita T, Kuwata T. Extra-perigastric Extranodal Metastasis is a Significant Prognostic Factor in Node-Positive Gastric Cancer. World J Surg, 43:2499-2505, 2019
14. Nishihara K, Oono Y, Kuwata T, Ikematsu H, Yano T. Depressed gastric-type adenoma in nonatrophic gastric mucosa without Helicobacter pylori infection. Endoscopy, 51:E138-E140, 2019
15. Ikemura S, Yasuda H, Matsumoto S, Kamada M, Hamamoto J, Masuzawa K, Kobayashi K, Manabe T, Arai D, Nakachi I, Kawada I, Ishioka K, Nakamura M, Namkoong H, Naoki K, Ono F, Araki M, Kanada R, Ma B, Hayashi Y, Mimaki S, Yoh K, Kobayashi SS, Kohno T, Okuno Y, Goto K, Tsuchihara K, Soejima K. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A, 116:10025-10030, 2019
16. Oono Y, Kuwata T, Takashima K, Shinmura K, Hori K, Yoda Y, Ikematsu H, Shitara K, Kinoshita T, Yano T. Human epidermal growth factor receptor 2-, epidermal growth factor receptor-, and mesenchymal epithelial transition factor-positive sites of gastric cancer using surgical samples. Gastric Cancer, 22:335-343, 2019